+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04913285

Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Adults With BRAF or NRAS Mutation-Positive Solid Tumors

Led by Pierre Fabre Medicament · Updated on 2026-09-02

400

Participants Needed

48

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating KIN-2787, a RAF small molecule kinase inhibitor, in adults with advanced or metastatic solid tumors that have BRAF or NRAS mutations. This study aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and initial effects of KIN-2787 alone and in combination with binimetinib, a MEK inhibitor. The study includes patients with various cancers such as lung cancer and melanoma that contain specific BRAF mutations. The trial has two parts a dose escalation phase to find the recommended dose of KIN-2787 alone and combined with binimetinib, and a dose expansion phase to further evaluate safety and effectiveness at this dose. KIN-2787 is taken orally twice daily in 28-day cycles. In combination groups, binimetinib is also given orally twice daily either continuously or intermittently, depending on the subgroup. Participants will receive study treatments and undergo regular assessments including tumor measurements using RECIST v1.1 criteria. Researchers will monitor safety, drug levels, and response to therapy up to 18 months in dose escalation and up to approximately 36 months in dose expansion. The study measures include objective response rate, disease control, and duration of response or stable disease, with ongoing evaluations during and after treatment.

CONDITIONS

Brief Title

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Research Team

D

Data Protection Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here